Business
TherapeuticsMD Announces Fourth Quarter and Full-Year 2019 Financial Results
- 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company’s Financial Guidance - - Full-Year 2019 Total Net Product Revenue of $34.1 Million at
About this update from Therapeuticsmd, Inc.
[{"type":"text","content":"\n- 4Q19 Total Net Product Revenue of $15.9 Million Exceeded the Company’s Financial Guidance -\n\n\n- Full-Year 2019 Total Net Product Revenue of $34.1 Million at the Top End of Financial Guidance -\n\n\n- Company Launched ANNOVERA, a Novel, Long-Lasting Contraceptive -\n\n\n- Company Expects Full-Year 2020 Net Product Revenue of $90 Million to $110 Million -\n\n\n- Conference Call Scheduled for 8:30 a.m. ET Today -\n\n BOCA RATON, Fla.--(BUSINESS WIRE)--\nTherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today reported financial results for the full-year and fourth quarter ended December 31, 2019 and provided 2020 financial guidance.\n\n\n“I am very pleased with our commercial team’s execution in 2019, which has put us in a strong position for 2020. We ended the year exceeding our fourth quarter net revenue guidance and achieved the top end of our full-year guidance,” said Robert G. Finizio, Chief Executive Officer of TherapeuticsMD. “Our goal is to build on this momentum as we make additional investments in our products to generate a significant revenue inflection point in 2020.”\n\n\nFourth Quarter & Recent Highlights\n\n\n\nNet product revenue for the fourth quarter of 2019 increased 94% to $15.9 million compared to the third quarter of 2019.\n\n\nANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system) achieved net revenue of $5.8 million for the fourth quarter of 2019 from sales to wholesalers and pharmacies with an average net revenue per unit of approximately $1,350.\n\n\nANNOVERA has already achieved market access for the majority of lives under commercial plans with 75% commercial coverage.\n\n\nIMVEXXY® (estradiol vaginal inserts) fourth quarter 2019 net revenue increased by 33% to $6.3 million compared to the third quarter of 2019. In the fourth quarter of 2019, approximately 123,000 IMVEXXY prescriptions were dispensed and paid for by patients. Average calculated net revenue per unit was approximately $51 for the fourth quarter of 2019. Strong IMVEXXY refill rates continued with patients adhering to therapy at an average rate of 4.4 fills through December 2019. Those patients on IMEXXY for one year averaged over six fills.\n\n\nIMVEXXY has market access for the majority of lives under commercial plans with 72% unrestricted commercial coverage. IMVEXXY is now covered...